Member Info for KingHomerJ

Regulators in the UK and US are working together more closely on medical technology and AI regulation, and this has several intended benefits:

• Accelerated innovation – New medical technologies and AI tools can be developed, tested, and approved faster because the regulatory processes will be more aligned.

• Strengthened patient safety – By sharing expertise and standards, both countries aim to make sure that new technologies are safe and effective before they reach patients.

• Reduced transatlantic barriers – Companies will face fewer hurdles in bringing medical technologies to both the UK and US markets, making it easier for useful innovations to be available in both regions.

In short: patients will get access to new, safe medical technologies more quickly, while companies will find it easier to launch them in both countries.

https://www.gov.uk/government/news/patients-to-benefit-as-uk-and-us-regulators-forge-new-collaboration-on-medical-technologies-and-ai

Trout,

Seems like you are being blind sided here…

Why would they use VT….mate you are making yourself look silly now….granted I agree with your comments on a random DoseMe trial in oz being irrelevant but…..the VT thing….

Come on you seem to be a knowledgeable guy/ girl / it that understands certain aspects of this company and I applaud that…..however not maybe enough.

Are you aware of the phase 2 drugs previous history ? What was it used for? And what tech (VT) did the modelling? Have you got info on this? I’d love to see it?

Guess not ? Guessing have a narrative- that’s fine,most shares do…… is what it is….very negative for a shareholder mind…

Have you also noted about the drugs potential about other inflationary diseases? Ok no / that’s also fine.

Frankly, I know far more about PK/PD & biosciences than your will ever understand so I never have to justify myself to you or anyone..

I’ll leave it at that……

Good luck…

Trout,

You know that Biometrics isn't just about set up and design or data end point its fundamental to the whole process to enable the efficiency of the trial.

This along with the VT modelling enables the company to deliver various forms for data across the whole cycle of the drug development....As mentioned in the companies presentations.

Trout,

Weatherdens own Elevara and do not have the VT tech or the Biostats to do this.....Yet they do have the expertise on everything you mentioned below.

You must agree with me that the 'Laws of Probability' of PYC gaining further contracts on this project are more than likely....

Have a look on Linkedin and I'm sure you will find various connections.......

At this MC with positive news there is a high possibility for a Rerate.....We are all here to make money after all.

Trout,

You could state, there are many other companies out there in any sector on any share.

I'm stating the laws of probability are definitely favourable towards PYC on this instance

Trout on this.

PYC has a Master Service Agreement with Weatherdens and this partnership has been working for over a year.... Weatherdens founded Elevara....

PYC Looks like it has a master service agreement with Elevara....Physiomics do have the virtual tumour and also have the biometrics department (they have 2 team members and contractors in this biometrics alone)

PYC has always said it want to scale and wants to use biometrics as a equal part of revenue generation...on a project with Elevara this would cover, modelling PK/PD, Simulations, Biostats, Data Science, Dosing.

It is fair to say that the likelihood of Physiomics gaining some meaningful contracts on this project alone are pretty High.

Trout this is correct....

However Pete is also limited to what he can say under various Master Service Agreements...

Did you look at the Elevara Link..... Who will be starting Phase 2 before end of 2025 and want to recruit 180 for this trial which will last around 2.5 years... The connection is very relevant and pretty much an indication that PYC does have a Master Service Agreement with them...

This would be a significant amount of contracts for PYC

From last Doseme Update

Expansion of collaboration

Physiomics and DoseMe have recently signed non-binding Heads of Terms with the intention of expanding their partnership beyond the Company’s current personalised dosing software. This agreement defines terms across four areas of collaboration:

development and commercialisation of novel dosing software tools originating from Physiomics;

development and commercialisation of novel dosing software tools originating from DoseMe or its clients;

provision of consultancy services by the Company to DoseMe; and

co-development of clinical trial dosing software in support of biopharmaceutical clients.

The two parties are actively working to identify potential projects falling under these umbrella categories and further announcements on this will be made when appropriate.

VAL always needs funds and generates zero cash....

PYC is in a completely different situation and in a completely different area of the market

Jarri.......merley just stating the laws of probability PYC being involved with this...

As you may be aware it is common practise for bio's to await funding like any company before they start to develop there assets further...PYC has a MSA in place and IF there is indeed a connection PYC will likely gain a multitude of significant contracts in the Phase 2 study launching 2025...

Surely someone who has admitted being a share holder and has millions of shares would want the company to benefit from these types of deals, so you can find your required exit....

22nd October 2025 Elevara announced a $70 million funding.

Elevara was founded by Weatherdens and would be a good guess to state this was the project PYC worked on and additionally announced a Master Service Agreement....with plans to launch phase 2 by year end.

PYC

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.

The project will involve the application of population Pharmacokinetic (PK) modelling techniques using Phase 1 data to inform the Phase 2 study of a small molecule designed to treat rheumatoid arthritis. The project, valued at £67,500, is expected to complete within the next three months and will be the Company’s first rheumatoid arthritis project as well as one of the later development stage projects delivered to date.

The Company has also put in place a Master Service Agreement with the client to define and agree broad commercial terms in relation to envisaged further potential projects in the future.

Elevara

https://www.fiercebiotech.com/biotech/british-biotech-elevates-stealth-70m-series-and-midstage-arthritis-asset

Absolutely correct DeBull

All I can say is trust the process of the company…

Watch the investor’s presentations, do research and reach out to Peter if needs be.

The biometrics with the addition of added current modelling will warrant longer high value contracts which I can envision will be higher value than previously.

I would like to insinuate there will be news in terms of contract(s) within the next two weeks…

Let’s see and good luck all…

Correction….

It’s 0.55 not 0.65

As mentioned previously would be interesting to look at SIMCYP LIMITED....and its history and whom it was purchased by

I’d like to suggest that biometrics contracts are likely to be higher in value and also incorporate a modelling aspect

Robust Cash position as per company presentation...

Just wait for the Biometrics contracts....

Investors, take note: Physiomics is perfectly positioned at the intersection of cutting-edge quantitative pharmacology, predictive modelling, and clinical trial optimisation. With a track record of partnerships spanning Astellas, Numab, Bicycle Therapeutics, and Cancer Research UK, the company has already demonstrated its ability to deliver high-value modelling solutions that accelerate drug development and de-risk R&D pipelines.

💡 Why Physiomics is a growth powerhouse:

Proven partnerships with top-tier pharma: Trusted by global players for critical immuno-oncology and bispecific antibody modelling.

Strong scientific IP & proprietary platforms: Virtual Tumour™ and advanced PK/PD modelling give them a competitive edge in precision drug development.

Expanding client base and diversified pipeline exposure: Oncology, immunology, bispecifics, and antibody-drug conjugates.

Regulatory tailwinds & trend towards model-informed drug development (MIDD): Increasing adoption of predictive modelling in clinical development boosts demand for Physiomics’ services.

📈 Catalysts for share price growth:

Continued delivery of high-value contracts with global pharma.

Expansion into emerging therapy areas like bifunctional antibodies and oncolytic viruses.

Publication of cutting-edge peer-reviewed research increasing credibility and visibility.

Growing market recognition of cost-efficient, data-driven R&D solutions.

In short, Physiomics is not just a service provider — it’s a strategic partner transforming drug development, and the market is only beginning to catch on. With multiple high-value projects in the pipeline and increasing demand for model-informed decision-making, the trajectory for share price growth is extremely promising.

💥 The future looks bright, and the upside potential is compelling. Physiomics is a stock to watch closely — a small-cap gem poised for a major leap!

Depends what your waiting for really…

Correct Trench 👍

Correct Trench and as I've been saying for months has enough CASH till Q4 2026 based on current run rate.

Additional Contracts - which there will be and collaborations will extend this further.